MN580 Final Exam Study Guide

MN580 Final Exam Study Guide It is recommended that you review the following topics in preparation for the exam. This study guide is to help you structure and organize your studying. This study guide is not all inclusive of what will be covered on the final exam; you will still be responsible for all the information that was covered in this course.  Determining parent “health literacy”  Purpose of FDA Medwatch and pediatric medications to educate healthcare providers & patients about importance of reporting serious adverse events  Advisory Committee on Immunization Practices (ACIP) guidelines for specific vaccine recommendations  Pediatric Research Equity Act (PREA) Established in 2003, gives FDA more leverage over drugs for children. Can require pediatric studies for potential drugs or if drug has new indication, ingredient, or route of delivery.  “Off –label” use of medications in pediatric populations Report to Med Watch.  Pediatric drug studies Very limited due to lack of studies.  Pediatric medication dosages vs. adult med dosages Children dosages are based on kidney maturation and metabolism rate for dosing guidelines. Children have high rate of nonadherence.  anticipatory guidance to parents for newborns, infants, toddlers, and school age children  Issues of recommending Probiotics for children Not enough studies to recommend  Management of 5-day-old infant with unilateral mild conjunctivitis, corneal opacity, and serosanguinous discharge  follow up recommendations for infant diagnosed with retinopathy of prematurity (ROP)  Chlamydia trachomatis conjunctivitis Test when sexually active or have urinary symptoms present . UA w blood leukocyte esterase – predictive of STI. Patient who are being tested should be offered HIV testing.  allergic conjunctivitis  Infant with Esotropia  Infant with human papillomavirus (HPV) conjunctivitis  Normal vs. abnormal UA dipstick findings in pediatric population Dipstick urinalysis is most widely used. Most